Volume 6, Issue 1 (6-2024)
pbp 2024, 6(1): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Samadi N, Motarjemizadeh G, Moharmzadeh N. Therapeutic Effects of Low Dose Acetylsalicylic Acid on Acute Central Serous Chorioretinopathy: A Prospective, Interventional, Single Centre Case Series. pbp 2024; 6 (1)
URL: http://pbp.medilam.ac.ir/article-1-214-en.html
URL: http://pbp.medilam.ac.ir/article-1-214-en.html
1- Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2- Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran , drkadirmurathan@gmail.com
2- Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran , drkadirmurathan@gmail.com
Abstract: (226 Views)
Background: Central serous chorioretinopathy (CSCR) is a common cause of central vision loss, primarily affecting men 20–60 years of age. This study aimed to investigate the efficacy of low-dose aspirin for the treatment of acute CSCR.
Methods: Totally 60 patients (60 eyes) with a history of acute CSC on fenofibrate were randomized into two groups: group A was treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months by evaluation of visual acuity, mean subretinal fluid vertical diameter (SFVD), Optical Coherence Tomography (OCT), and central macular thickness (CMT) at baseline and follow up period. Group B received no medication and was considered as the control group. Follow-up times were the first week, 1, 2, 3 and 6 months after treatment initiation.
Results: No differences were seen between the studied groups in terms of baseline BCVA (P = 0.968) and baseline SFVD (P = 0.774). BCVA improved, and SFVD was reduced significantly in the group A at all follow-up intervals compared with baseline values. Aspirin intervention (group A), compared with no intervention group (group B), was statistically more effective in improving BCVA (P < 0.001) and in reducing SFVD (P < 0.001) after 6 months. While 93.3% (n=28) of Group A’s cases had no recurrences during the follow-up period, only 60.0% (n=18) of patients in the group B had a resolution of CSCR with no recurrences.
Conclusion: More rapid visual rehabilitation with fewer recurrences of CSCR were detected in the group A than in group B. These results demonstrated that orally administered aspirin may be a promising option for selected patients in the treatment of acute CSCR.
Methods: Totally 60 patients (60 eyes) with a history of acute CSC on fenofibrate were randomized into two groups: group A was treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months by evaluation of visual acuity, mean subretinal fluid vertical diameter (SFVD), Optical Coherence Tomography (OCT), and central macular thickness (CMT) at baseline and follow up period. Group B received no medication and was considered as the control group. Follow-up times were the first week, 1, 2, 3 and 6 months after treatment initiation.
Results: No differences were seen between the studied groups in terms of baseline BCVA (P = 0.968) and baseline SFVD (P = 0.774). BCVA improved, and SFVD was reduced significantly in the group A at all follow-up intervals compared with baseline values. Aspirin intervention (group A), compared with no intervention group (group B), was statistically more effective in improving BCVA (P < 0.001) and in reducing SFVD (P < 0.001) after 6 months. While 93.3% (n=28) of Group A’s cases had no recurrences during the follow-up period, only 60.0% (n=18) of patients in the group B had a resolution of CSCR with no recurrences.
Conclusion: More rapid visual rehabilitation with fewer recurrences of CSCR were detected in the group A than in group B. These results demonstrated that orally administered aspirin may be a promising option for selected patients in the treatment of acute CSCR.
Keywords: central serous chorioretinopathy, aspirin, acetyl salicylic acid, best corrected visual acuity (BCVA), recurrence
Type of Study: Research |
Subject:
Clinical
Received: 2024/02/17 | Accepted: 2024/02/20 | Published: 2024/02/20
Received: 2024/02/17 | Accepted: 2024/02/20 | Published: 2024/02/20
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |